Apollo Ingredients Ltd
- Market cap
- ₹ 89 Cr.
- P/E
- 41x
- P/B
- 12.8x
- 52-week range
- 6.58 – 146.05
- ROE
- 17%
- ROCE
- 22.9%
- Dividend yield
- 0%
- Debt / equity
- 0
- Sector
- Commercial Services & Supplies
- Industry
- Diversified Commercial Services
- Listed on
- BSE
About
Apollo Ingredients Limited is an India-based manufacturer and producer of healthcare solutions. The Company is engaged in the business of manufacturing, producing, importing, exporting and dealing in total healthcare solutions in ayurvedic, homeopathic and allopathic medicines. It also carries out medical and clinical audits, medical, healthcare, and hospital facility planning from concept to commissioning and post commissioning managing healthcare institutions of any kind, public or private. The Company’s business also includes establishing and running hospitals/healthcare institutions, diagnostic centers, health spas, wellness centers, pathology, life science and stem cell depositories. It also provides support services such as housekeeping, security, technical and clinical, paramedical and nursing human resources to healthcare and other organizations. It launches hospitals and develops strategic concepts and business development policies for healthcare and health solutions.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Diversified Commercial Services: 149 companies →Apollo Ingredients Ltd against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)41 against a typical 18.6: pricier than most peers (1st = cheapest).90th of 139
- Sales growth+841.1% against a typical +14.1% from a year earlier.5th of 115
- Share price, 3 months−25.1% against a typical −8%.108th of 121
- Size₹ 89.4 Cr. market value against a typical ₹ 68.8 Cr. (1st = largest).57th of 128
Financials
Standalone figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 5 |
| Expenses | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 4 |
| Operating Profit | −0 | −0 | 0 | 0 | −0 | 0 | 0 | −0 | 0 | 1 | 0 | 1 |
| OPM % | — | — | 20% | 0% | −23.8% | 12.8% | 23.2% | −16.1% | 3.5% | 31.4% | 9.9% | 24.5% |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | −0 | −0 | 0 | 0 | −0 | 0 | 0 | −0 | 0 | 1 | 0 | 1 |
| Tax % | 0% | 0% | 10% | — | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Profit | −0 | −0 | 0 | 0 | −0 | 0 | 0 | −0 | 0 | 1 | 0 | 1 |
| EPS in Rs | −0.03 | −0.03 | 0.16 | 0 | −0.18 | 0.13 | 0.15 | −0.09 | 0.02 | 0.84 | 0.07 | 1.17 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- —
- 5 Years
- 1%
- 3 Years
- —
- TTM
- 206%
- 10 Years
- 32%
- 5 Years
- 28%
- 3 Years
- 130%
- TTM
- 10,800%
- 10 Years
- —
- 5 Years
- —
- 3 Years
- —
- TTM
- —
- 10 Years
- 8%
- 5 Years
- 10%
- 3 Years
- 13%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Apollo Ingredients Ltd | ₹ 99.18 | ₹ 89 Cr. | 41x | 12.8x | 17% | — |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 38.9x | 5.6x | 14.2% | 19.1% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 74x | 11.6x | 16.2% | 24.3% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 76.4x | 20.2x | 27.1% | 15.3% |
| Cipla | ₹ 1,337.00 | ₹ 1,08,011 Cr. | 28x | 3.4x | 11.8% | 13.7% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 21.3x | 4.3x | 19.7% | 18.5% |
Management
- Lalita Ghanshyam Mutreja
- Chief Financial Officer
- Ayushi Agrawal
- Company Secretary, Compliance Officer
- Kirit Ghanshyam Mutreja
- Managing Director, Executive Director
- Lovely Ghanshyam Mutreja
- Executive Director, Marketing Director
Prices are delayed and for information only. Nothing on this page is investment advice.